Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. No beneficial treatment effects were recorded for progressive supranuclear palsy.
